Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states

被引:0
|
作者
Christ-Crain, M
Morgenthaler, NG
Meier, C
Müller, C
Nussbaumer, C
Bergmann, A
Staub, JJ
Müller, B
机构
[1] Univ Basel Hosp, Dept Internal Med, Dept Endocrinol, CH-4031 Basel, Switzerland
[2] BRAHMS AG, Ctr Biotechnol, Hennigsdorf, Germany
[3] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[4] Univ Basel Hosp, Dept Clin Chem, CH-4031 Basel, Switzerland
关键词
natriuretic peptides; hypothyroidism; hyperthyroidism;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Questions under study: Natriuretic peptides are produced predominantly in the heart and secreted in response to volume expansion and pressure overload. A wide spectrum of cardiac changes is observed in thyroid dysfunctions. This study investigates mid regional pro A-type (proANP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in different thyroid states and evaluates the effect of L-thyroxine treatment on natriuretic peptides in patients with subclinical hypothyroidism. Methods: Case-control and double-blind, placebo-controlled trial. Sera from 161 female patients (35 with overt, 63 with subclinical hypothyroldism; 10 with overt, 14 with subclinical hyperthyroidism; 40 euthyroid controls) were analysed. ProANP and NT-proBNP were measured at baseline and 48 weeks after L-thyroxine treatment in subclinical hypothyroidism. Results: Circulating proANP and NT-proBNP levels were higher in hyperthyroid patients than in hypothyroid and euthyroid patients (p < 0.001). Plasma proANP levels tended to be lower in overt hypothyroidism than in subclinlcal hypothyroidism. ProANP and NT-proBNP levels correlated weakly to thyroid stimulating hormone (TSH) (r = -0.3 and -0.2, respectively). The natriuretic peptide levels of subclinical and overt hypothyroid subjects showed no difference with those of euthyroid subjects. L-thyroxine treatment had no effect on natriuretic peptide levels in subclinical hypothyroidism. Conclusion: Natriuretic peptide levels are altered in different thyroid states with a more pronounced effect in hyperthyroidism than in hypothyroidism. Hyperthyroidism should be considered in patients presenting with unclear symptoms and mildly elevated natriuretic peptide levels, as overt hyperthyroidism results in increased serum A- and B-type natriurectic peptide levels, typically seen in mild heart failure.
引用
收藏
页码:549 / 554
页数:6
相关论文
共 50 条
  • [1] Comparison of Midregional Pro-A-Type Natriuretic Peptide and the N-Terminal Pro-B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events
    van Hateren, Kornelis J. J.
    Alkhalaf, Alaa
    Kleefstra, Nanne
    Groenier, Klaas H.
    de Jong, Paul E.
    de Zeeuw, Dick
    Gans, Rijk O. B.
    Struck, Joachim
    Bilo, Henk J. G.
    Gansevoort, Ron T.
    Bakker, Stephan J. L.
    CLINICAL CHEMISTRY, 2012, 58 (01) : 293 - 297
  • [2] Comparison of the Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Death and Cardiovascular Events: Superiority of N-Terminal Pro-B-Type Natriuretic Peptide
    McKie, Paul
    Cataliotti, Alessandro
    Sangaralingham, S. J.
    Ichiki, Tomoko
    Redfield, Margaret
    Chen, Horng
    Rodeheffer, Richard
    Burnett, John
    CIRCULATION, 2010, 122 (21)
  • [3] N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes
    Ezekowitz, Justin A.
    O'Connor, Christopher M.
    Troughton, Richard W.
    Alemayehu, Wendimagegn G.
    Westerhout, Cynthia M.
    Voors, Adriaan A.
    Butler, Javed
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Emdin, Michele
    Patel, Mahesh J.
    Pieske, Burkert
    Roessig, Lothar
    Hernandez, Adrian F.
    Armstrong, Paul W.
    JACC-HEART FAILURE, 2020, 8 (11) : 931 - 939
  • [4] N-Terminal Pro-B-Type Natriuretic Peptide and Incident CKD
    Sasaki, Takaya
    Oishi, Emi
    Nagata, Takuya
    Sakata, Satoko
    Chen, Sanmei
    Furuta, Yoshihiko
    Honda, Takanori
    Yoshida, Daigo
    Hata, Jun
    Tsuboi, Nobuo
    Kitazono, Takanari
    Yokoo, Takashi
    Ninomiya, Toshiharu
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (04): : 976 - 985
  • [5] N-Terminal Pro-B-Type Natriuretic Peptide in Tricuspid Valve Replacement
    Cheng, Yanmei
    Ou, Jingsong
    Tang, Baiyun
    Wang, Qianqian
    Liang, Mengya
    Wang, Zhiping
    Wu, Zhongkai
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2020, 32 (04) : 801 - 810
  • [6] N-Terminal Pro-B-Type Natriuretic Peptide and Longitudinal Risk of Hypertension
    Nicoli, Charles D.
    Plante, Timothy B.
    Long, D. Leann
    Judd, Suzanne E.
    McClure, Leslie A.
    Arora, Pankaj
    Cushman, Mary
    AMERICAN JOURNAL OF HYPERTENSION, 2021, 34 (05) : 476 - 483
  • [7] N-Terminal Pro-B-Type Natriuretic Peptide A Risk Predictor for All
    Douglas, Pamela S.
    Felker, G. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (17) : 1798 - 1800
  • [8] N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis
    Ducros, Jacques
    Larifla, Laurent
    Merault, Henri
    Galantine, Valerie
    Bassien-Capsa, Valerie
    Foucan, Lydia
    INTERNATIONAL JOURNAL OF NEPHROLOGY, 2020, 2020
  • [9] Circulating Fragments of N-Terminal Pro-B-Type Natriuretic Peptides in Plasma of Heart Failure Patients
    Foo, Jared Yong Yang
    Wan, Yunxia
    Schulz, Benjamin L.
    Kostner, Karam
    Atherton, John
    Cooper-White, Justin
    Dimeski, Goce
    Punyadeera, Chamindie
    CLINICAL CHEMISTRY, 2013, 59 (10) : 1523 - 1531
  • [10] N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states
    Schultz, M
    Faber, J
    Kistorp, C
    Jarlov, A
    Pedersen, F
    Wiinberg, N
    Hildebrandt, P
    CLINICAL ENDOCRINOLOGY, 2004, 60 (01) : 54 - 59